Truist lowered the firm’s price target on Humana to $260 from $400 and keeps a Hold rating on the shares as part of a broader research note on Managed Healthcare names. The firm is updating its models with new 2026 and quarterly 2025 estimates, the analyst tells investors in a research note. Truist further notes that its updated price target on Humana reflects the latest Medicare Advantage star ratings data, and it sees a “more challenging” path to margin recovery for the company.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUM:
- Humana down after CMS posts Medicare Part C and D performance data
- Humana Medicare Advantage star ratings not changed, says Oppenheimer
- Closing Bell Movers: Aehr Test Systems up 11% after earnings beat
- KeyBanc starts Humana at Sector Weight, says margin recovery weighted to 2027
- Humana initiated with a Sector Weight at KeyBanc